Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

British Journal of Cancer

Volumn 90, Issue 8, 2004, Pages 1492-1497

  Olivier, R I ^a   Van Beurden, M ^a,b   Lubsen, M A C ^a,b   Rookus, M A ^a   Mooij, T M ^a   Van De Vijver, M J ^a   Van't Veer, L J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1 mutation; BRCA2 mutation; Fallopian tube carcinoma; PPSC; Prophylactic salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; CANCER PREVENTION; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE DETECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OCCULT CANCER; OVARY CARCINOMA; PAPILLARY CARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; ARTICLE; CARCINOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARIECTOMY; OVARY TUMOR; PERITONEUM TUMOR; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR SUPPRESSOR GENE; UTERINE TUBE TUMOR;

ADULT; AGED; CARCINOMA; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 2442528272     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601692     Document Type: Review

References (38)

1. Agoff SN, Mendelin JE, Grieco VS, Garcia RL (2002) Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 26: 171-178
2. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 997-1003
3. Chen KT, Schooley JL, Flam MS (1985) Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66: 93S-94S
4. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25: 1283-1289
5. Dicker RC, Greenspan JR, Strauss LT, Cowart MR, Scally MJ, Peterson HB, DeStefano F, Rubin GL, Ory HW (1982) Complications of abdominal and vaginal hysterectomy among women of reproductive age in the United States. The Collaborative Review of Sterilization. Am J Obstet Gynecol 144: 841-848
6. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271
7. Eisen A, Rebbeck TR, Wood WC, Weber BL (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18: 1980-1995
8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695
9. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in the breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
10. Foulkes WD, Narod SA, Swenerton K, Panabaker K, Gilbert L (2003) Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95: 1640
11. Hartley A, Rollason T, Spooner D (2000) Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol (R Coll Radiol) 12: 58-59
12. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E (1999) Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 75: 300-304
13. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D (1993) Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306: 1030-1034.
14. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH (1999) Screening for ovarian cancer a pilot randomised controlled trial. Lancet 353: 1207-1210
15. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl JMed 346: 1609-1615
16. Laframboise S, Nedelcu R, Murphy J, Cole DE, Rosen B (2002) Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 12: 86-91
17. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310-2318
18. Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U (2000) BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 96: 28-32
19. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P (2002) Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87: 52-56
20. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21: 4222-4227
21. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18: 2728-2732
22. Lynch HT, Bewtra C, Lynch JF (1986) Familial ovarian carcinoma. Clinical nuances. Am J Med 81: 1073-1076
23. Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P, Lynch JF, Ponder BA (1991) Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 67: 1460-1466
24. Menon U, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, Skates SJ, Sibley K, Oram DH, Jacobs IJ (1999) Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer 80: 1644-1647
25. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA (2001) Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80: 176-180
26. Piver MS, Jishi MF, Tsukada Y, Nava G (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71: 2751-2755
27. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622
28. Rose PG, Shrigley R, Wiesner GL (2000) Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 77: 319-320
29. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC (1996) Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88: 1810-1820
30. Schneider C, Wight E, Perucchini D, Haller U, Fink D (2000) Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol 21: 578-582
31. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC (1997) BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60: 1031-1040
32. Scully R, Young R, Clement P (2003) Tumors of the fallopian tube: histologic classification and cancer staging epithelial and mixed epithelial - mesenchymal tumors. In Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Rosai J, Sobin L (eds) pp 461-476. Washington: Armed Forces Institute of Pathology
33. Sobol H, Jacquemier J, Bonaiti C, Dauplat J, Birnbaum D, Eisinger F (2000) Fallopian tube cancer as a feature of BRCA1-associated syndromes. Gynecol Oncol 78: 263-264
34. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408
35. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF, Jr (1982) Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2: 795-797
36. Tong D, Stimpfl M, Reinthaller A, Vavra N, Mullauer-Ertl S, Leodolter S, Zeillinger R (1999) BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization. Clin Chem 45: 976-981
37. Woolas R, Smith J, Saharnis P, Paterson M, Sharp F (1997) Fallopian tube carcinoma: an under-recognized primary neoplasm. Int J Gynecol Cancer 7: 284-288
38. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P (2000) Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 76: 45-50